Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTACK: Aspirin to Target Arterial Events in Chronic Kidney Disease
NCT03796156Phase 3Terminated
- Sponsor
- University of Southampton
- Start
- Feb 2019
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin in cardiovascular disease (CVD) (2 arms), sponsored by University of Southampton. Primary endpoint: Composite outcome of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death at 4 years. Started Feb 2019; status: terminated.
02
Drugs
aspirin
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03796156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796156.